This is the authors' abstract. We don't add key points for this paper.
Topical ruxolitinib led to marked improvement in refractory facial dermatitis in a 10-year-old patient with STAT1 gain-of-function. These findings support localized inhibition of dysregulated JAK-STAT signaling as a well-tolerated and effective treatment for cutaneous manifestations of STAT1 gain-of-function disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Guarnieri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: